retatrutide mechanism gip glp-1 glucagon triple agonist Retatrutide—A Game Changer in Obesity Pharmacotherapy Main physiological actions of the

Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones

Metabolism becomes less efficient

To view or add a comment, sign in Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech by The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market

Patients with cardiovascular risk factors may therefore find a GLP-1RA more appropriate owing to the improvements in cardiometabolic parameters that have been observed with this drug class [10, 37, 46, 47]

These numbers should be interpreted cautiously given the different trial designs, but the trend is consistent across multiple analyses